Discussing the Use of Anti-CD38 Combination Therapy in RRMM

EP: 1.Next-Line Therapy Choices in R/R Multiple Myeloma After VRd Plus ASCT

EP: 2.Reactions to Updated Isatuximab Data in Second-Line Multiple Myeloma

EP: 3.Comparing Triplet Therapies Across the Multiple Myeloma Landscape

EP: 4.Isatuximab Combination Shows Deeper Responses in R/R Multiple Myeloma

Now Viewing

EP: 5.Discussing the Use of Anti-CD38 Combination Therapy in RRMM

EP: 6.Isatuximab Combo Provides Durable Option in High-Risk Multiple Myeloma

EP: 7.Isatuximab Provides Longer Survival in Early Relpase Multiple Myeloma

EP: 8.Isatuximab-Based Triplet Therapy Improves Outcomes in R/R Multiple Myeloma

EP: 9.Sborov Reviews How Isatuximab Fits Into R/R Multiple Myeloma

EP: 10.IKEMA Shows Advantage for Anti-CD38 in 1q21+ R/R Multiple Myeloma

EP: 11.Isa-Kd Stands Out Among Subsequent Regimens in Multiple Myeloma

Joshua Richter, MD, associate professor of medicine, division of hematology and oncology, at the Tisch Cancer Institute, Icahn School of Medicine, and the director of multiple myeloma at the Blavatnik Family-Chelsea Medical Center at Mount Sinai, discusses the available combination therapies for patients with relapsed multiple myeloma.

Defining the different groups of early and late relapse, Richter highlights that therapy would be different for each. In the early relapse setting, the use of an anti-CD38 monoclonal antibody in combination with carfilzomib [Kyprolis] remains the best option. The current anti-CD38 therapies available to combine with carfilzomib are daratumumab [Darzalex] and isatuximab [Sarclisa].

Data supporting these combinations come from the phase 3 CANDOR study (NCT03158688) that showed that patients with relapsed/refractory multiple myeloma maintained their median progression-free survival (PFS) of 28.6 months (95% CI, 22.7–not estimable) compared with patients on carfilzomib alone (HR, 0.59; 95% CI, 0.45-0.78; P < .0001). In the phase 3 IKEMA study (NCT03275285), the addition of the anti-CD38 therapy isatuximab significantly improved PFS for these patients compared with carfilzomib and dexamethasone alone (HR, 0.53; 99% CI, 0.32-0.89; P = .0007). Looking at later-line relapses, Richter highlighted the continuing use of chimeric antigen receptor (CAR) T-cell therapy and novel bispecific antibodies.

Transcription:

0:07 | In general, when we talk about [patients with] relapsed myeloma, we talk about early relapses and late relapses. Early relapse is 1 to 3 prior lines of therapy and late relapses are 4 or more prior lines [of therapy]. And one of the areas that has really dominated the field of early relapse is CD38-based therapy, so daratumumab- and isatuximab-based combinations.

0:30 | Although we can combine these with a variety of therapies, we recognize that CD38 therapy plus Kyprolis has given us some of the most impressive data in the early relapse [setting], specifically with either daratumumab and Kyprolis or isatuximab and Kyprolis. For later line relapses, we're really looking towards the T-cell redirection therapies, like CAR T-cell therapy and bispecific antibodies.